This symposium discussed how the efficacy of anti-amyloid beta (Aβ) monoclonal antibodies (mAbs) was evaluated in clinical trials (both for therapeutic and preventive treatment of Alzheimer’s disease) versus in real-world clinical practice and explored how clinically meaningful outcomes for patients living with AD may be defined in today’s clinical practice.
The discussants also covered the clinical management of ARIA-E and ARIA-H in the first year following anti-Aβ mAb approvals, including how ApoE genotype and co-administration of anticoagulants or thrombolytics may have influenced the treatment paradigm. Finally, the discussants explored future directions for anti-Aβ therapy. This included discussion of the emergence of PRX012, a novel anti-Aβ mAb designed for subcutaneous administration that potently binds Aβ and was being evaluated in a Phase 1 clinical trial by Prothena. Other investigational approaches, such as combination therapy with anti-Aβ mAbs, were also discussed.
Faculty:
- Professor Dennis Selkoe, Harvard Medical School
- Professor Jeffrey L. Cummings, University of Nevada Las Vegas
- Dr. Alireza Atri, Banner Health
- Dr. Chad J. Swanson, Prothena Biosciences
- Donna Masterman, M.D., Prothena Biosciences